Status:

NO_LONGER_AVAILABLE

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

Lead Sponsor:

Mannkind Corporation

Conditions:

Type 1 Diabetes

Type 2 Diabetes

Eligibility:

All Genders

Brief Summary

The purpose of this study is to allow patients with specific needs for inhaled insulin to continue with inhaled insulin therapy using Technosphere Insulin after Exubera was withdrawn from the market.

Detailed Description

A Phase 3, open label, multicenter, safety follow up trial to convert the treatment of subjects currently using Exubera to treatment with TI Inhalation Powder

Eligibility Criteria

Inclusion

  • Subject has type 1 or type 2 diabetes mellitus and is currently being treated with or has been treated with Exubera.
  • Subject has a severe phobia to sc injections of insulin (needle phobia) preventing conventional treatment OR has impaired sc insulin absorption

Exclusion

  • Smoking in the previous 6 months
  • History of asthma or chronic obstructive pulmonary disease (COPD) or any other significant pulmonary disease, or exposure to pulmonary toxins.
  • Clinically significant pulmonary abnormalities on chest high-resolution computed tomography (HRCT).
  • PFT results prior to transferring to TI Inhalation Powder showing any of the following: FEV1 \< 70% of predicted, FVC \< 70% of predicted, DLCO \< 70% of predicted, TLC \< 80% of predicted.
  • Allergy to insulin

Key Trial Info

Start Date :

October 1 2008

Trial Type :

EXPANDED_ACCESS

End Date :

May 1 2015

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01798914

Start Date

October 1 2008

End Date

May 1 2015

Last Update

January 20 2016

Active Locations (14)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (14 locations)

1

Endocrinology Associates

Montgomery, Alabama, United States, 36106

2

Diabetes and Endocrine Consultants P.C.

Montgomery, Alabama, United States, 36117

3

University of Miami Diabetes Research Institute

Miami, Florida, United States, 33136

4

Dr. Rife and Associates Family Medicine

Orland Park, Illinois, United States, 60467

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder | DecenTrialz